VRDN Viridian Therapeutics
- 23.060
- +1.660+7.76%
- 23.300
- +0.240+1.04%
Viridian Therapeutics News
BTIG Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $61
Buy Rating for Viridian Therapeutics: Leading the TED Market With Innovative SC Treatment VRDN-003
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $44
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $45
Wedbush Raises Viridian Therapeutics' Price Target to $45 From $42, Maintains Outperform Rating
Viridian Therapeutics Analyst Ratings
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $44
Buy Rating Affirmed for Viridian Therapeutics Following Positive THRIVE Study Results and Strong Market Potential for Veli
Viridian Therapeutics Is Maintained at Buy by Goldman Sachs
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $31
B.Riley Financial Maintains Viridian Therapeutics(VRDN.US) With Hold Rating, Raises Target Price to $22
B. Riley Adjusts Viridian Therapeutics Price Target to $22 From $20, Maintains Neutral Rating
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $27 to $56
Viridian Therapeutics Is Maintained at Buy by Needham
Viridian Therapeutics Price Target Raised to $56.00/Share From $46.00 by BTIG
Viridian Therapeutics Analyst Ratings
Buy Rating for Viridian Therapeutics Backed by Positive Clinical Results and Strong Market Prospects
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $42
LifeSci Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $46
Buy Rating Affirmed for Viridian Therapeutics Amid Positive Outlook on VRDN-001 for Thyroid Eye Disease
Analysis
Price Target
No Data
No Data